Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Restructuring Costs (2020 - 2024)

Historic Restructuring Costs for Aytu Biopharma (AYTU) over the last 3 years, with Q4 2024 value amounting to $1.3 million.

  • Aytu Biopharma's Restructuring Costs changed N/A to $1.3 million in Q4 2024 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 5520.41%. This contributed to the annual value of $2.1 million for FY2025, which is 255.1% down from last year.
  • Aytu Biopharma's Restructuring Costs amounted to $1.3 million in Q4 2024.
  • Aytu Biopharma's 5-year Restructuring Costs high stood at $4.8 million for Q1 2021, and its period low was $11000.0 during Q2 2021.
  • In the last 3 years, Aytu Biopharma's Restructuring Costs had a median value of $814277.0 in 2020 and averaged $1.3 million.
  • The largest annual percentage gain for Aytu Biopharma's Restructuring Costs in the last 5 years was 144878.28% (2021), contrasted with its biggest fall of 9864.91% (2021).
  • Quarter analysis of 3 years shows Aytu Biopharma's Restructuring Costs stood at $1.3 million in 2020, then crashed by 99.16% to $11000.0 in 2021, then skyrocketed by 11872.73% to $1.3 million in 2024.
  • Its last three reported values are $1.3 million in Q4 2024, $784000.0 for Q3 2024, and $1.9 million during Q2 2024.